PTX Stock Overview
Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia.
Prescient Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.18|
|52 Week High||AU$0.30|
|52 Week Low||AU$0.12|
|1 Month Change||-10.00%|
|3 Month Change||24.14%|
|1 Year Change||-26.53%|
|3 Year Change||361.54%|
|5 Year Change||239.62%|
|Change since IPO||-99.75%|
Recent News & Updates
Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
|PTX||AU Biotechs||AU Market|
Return vs Industry: PTX underperformed the Australian Biotechs industry which returned -4.3% over the past year.
Return vs Market: PTX underperformed the Australian Market which returned -10.5% over the past year.
|PTX Average Weekly Movement||16.7%|
|Biotechs Industry Average Movement||10.8%|
|Market Average Movement||10.1%|
|10% most volatile stocks in AU Market||16.8%|
|10% least volatile stocks in AU Market||4.5%|
Stable Share Price: PTX is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 17% a week.
Volatility Over Time: PTX's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase II clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. Prescient Therapeutics Limited has a collaboration agreement with Carina Biotech to develop cell therapies.
Prescient Therapeutics Fundamentals Summary
|PTX fundamental statistics|
Is PTX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PTX income statement (TTM)|
|Cost of Revenue||AU$0|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.0076|
|Net Profit Margin||-359.85%|
How did PTX perform over the long term?See historical performance and comparison
Is PTX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PTX?
Other financial metrics that can be useful for relative valuation.
|What is PTX's n/a Ratio?|
Price to Book Ratio vs Peers
How does PTX's PB Ratio compare to its peers?
|PTX PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
ACW Actinogen Medical
CHM Chimeric Therapeutics
PTX Prescient Therapeutics
Price-To-Book vs Peers: PTX is expensive based on its Price-To-Book Ratio (6.3x) compared to the peer average (3.4x).
Price to Earnings Ratio vs Industry
How does PTX's PE Ratio compare vs other companies in the AU Biotechs Industry?
Price-To-Book vs Industry: PTX is expensive based on its Price-To-Book Ratio (6.3x) compared to the Australian Biotechs industry average (2.8x)
Price to Book Ratio vs Fair Ratio
What is PTX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||6.3x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate PTX's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of PTX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate PTX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate PTX's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PTX's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Prescient Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Prescient Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine Prescient Therapeutics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Prescient Therapeutics competitive advantages and company strategy can generally be found in its financial reports archived here.
How has Prescient Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PTX is currently unprofitable.
Growing Profit Margin: PTX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PTX is unprofitable, and losses have increased over the past 5 years at a rate of 13.2% per year.
Accelerating Growth: Unable to compare PTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.9%).
Return on Equity
High ROE: PTX has a negative Return on Equity (-26.66%), as it is currently unprofitable.
Discover strong past performing companies
How is Prescient Therapeutics's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: PTX's short term assets (A$15.7M) exceed its short term liabilities (A$390.1K).
Long Term Liabilities: PTX's short term assets (A$15.7M) exceed its long term liabilities (A$41.1K).
Debt to Equity History and Analysis
Debt Level: PTX is debt free.
Reducing Debt: PTX had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PTX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: PTX has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 9.3% each year
Discover healthy companies
What is Prescient Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PTX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PTX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as PTX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Steven Lee Yatomi-Clarke has been Chief Executive Officer and Managing Director of Prescient Therapeutics Limited since February 15, 2016. Mr. Yatomi-Clarke has been Director of Prescient Therapeutics...
CEO Compensation Analysis
Compensation vs Market: Steven's total compensation ($USD548.02K) is above average for companies of similar size in the Australian market ($USD282.25K).
Compensation vs Earnings: Steven's compensation has increased whilst the company is unprofitable.
Experienced Management: PTX's management team is seasoned and experienced (5.1 years average tenure).
Experienced Board: PTX's board of directors are considered experienced (7.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.1%.
Prescient Therapeutics Limited's employee growth, exchange listings and data sources
- Name: Prescient Therapeutics Limited
- Ticker: PTX
- Exchange: ASX
- Founded: 1986
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: AU$117.778m
- Shares outstanding: 654.32m
- Website: https://ptxtherapeutics.com
- Prescient Therapeutics Limited
- 100 Albert Road
- Level 4
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/07/05 00:00|
|End of Day Share Price||2022/07/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.